NG Biotech S.A.S. (NG) announced today the appointment of Fabio Baglioni as Chief Commercial Officer (CCO) to spearhead the next phase of the company’s ambitious growth strategy.
An experienced business leader, Mr Baglioni will succeed Stefan Raupach. Having successfully grown the company’s commercial division, Mr Raupach will take on the new role of Chief Business Officer as part of a broader restructuring of the company’s senior management team to support and continue the steep growth trend evidenced in recent years.
Mr Baglioni joins the company with significant commercial experience, having most recently been CCO for Australian medical device developer Atomo Diagnostics Ltd (ASX:AT1). Prior to this, Mr Baglioni was Vice President Global Sales & Marketing at Cavidi AB, a Swedish biotech company specialising in diagnostics for HIV viral load testing and patient monitoring. Mr Baglioni has also worked for Business Sweden, formerly the Swedish Trade Council, helping Swedish companies succeed in export markets. He holds a Diploma in Marketing & Management from IHM Business School, Stockholm.
NG’s Chief Executive Officer, Milovan Stankov-Pugès said, “We are delighted to have Fabio join our rapidly expanding team. Having been at the forefront of France’s diagnostic response to the Covid-19 pandemic, NG has achieved significant growth during the last 18 months, with production capacity having increased more than twentyfold in the period. By expanding and enhancing our senior management team, we are ensuring that we can continue our growth trajectory in areas of diagnostic testing beyond Covid-19.”
As well as announcing today the appointment of Mr Baglioni, NG explained that it is restructuring its business development division to create a series of business units to focus on specific aspects of its diverse diagnostic test portfolio – including rapid tests for Covid-19, antibiotic resistance, multiple OTC applications, and blood-based pregnancy tests commercialised under the NG-Test® brand – to maximise their commercial potential.
Mr Stankov-Pugès explained, “We are confident that the new appointments and structural changes outlined today will enable us to continue to expand current business units, while also exploiting exciting opportunities in new fields of activity.”
